ECOR electroCore

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Jennifer Hayes will be joining electroCore, effective October 6, 2025, as the Company’s Vice President, Human Resources and Employee Success. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Ms. Hayes in connection with the commencement of her employment. The RSUs were granted as an inducement material to Ms. Hayes’ commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). One-third of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to Ms. Hayes’ continued employment by the Company on the applicable vesting date. Upon vesting, the RSUs shall be settled in shares of the Company’s common stock.

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore non-invasive vagus nerve stimulation (nVNS) and Quell neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance. For more information, visit .

Contact:

ECOR Investor Relations

(973) 302-9253



EN
03/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE

electroCore Announces Publication in Frontiers in Neuroscience Highlig...

electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD ROCKAWAY, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in Frontiers in Neuroscience titled “Adjunctive non-invasive vagus nerve stimulation for chronic mild traumatic brain injury with comorbid post-traumatic stress disorder: a post-hoc analysis” by Drs. Michael Am...

 PRESS RELEASE

electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635...

electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams will join electroCore, effective April 1, 2026, as the Company’s VP, Sales, and Michael Fox will join electroCore, effective April 13, 2026, as the Company's Chief Operating Officer. The Compensation Committee of electroCore’s Board of Directors granted 30,000 restricted stock units (“RSUs”) to Mr. Abrams and 70,000 R...

 PRESS RELEASE

electroCore Expands Intellectual Property Portfolio

electroCore Expands Intellectual Property Portfolio electroCore strengthens its extensive intellectual property portfolio with issuance of two new U.S. patents, extending protection on core products and applications ROCKAWAY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the issuance of two new U.S. patents that further bolster the Company’s already extensive intellectual property portfolio. These additions underscore electroCore’s position as a leader in non-invasive vagus nerve...

 PRESS RELEASE

electroCore to Participate at the 38th Annual Roth Conference

electroCore to Participate at the 38th Annual Roth Conference ROCKAWAY, N.J., March 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a bioelectronic medicine and wellness company, announced today that management will participate in the 38th Annual Roth Conference March 22-24 at the Ritz-Carlton in Laguna Niguel, California. Joshua Lev, Chief Financial Officer, will host one-on-one meetings at the conference. Investors attending this event who are interested in scheduling a meeting with management can do so by contacting their respective Roth representative, or by emailing ...

 PRESS RELEASE

electroCore to Announce Fourth Quarter and Full Year Ended December 31...

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026 ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and full year ended December 31, 2025, after the close of the market on Thursday, March 19, 2026. Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch